Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

Recce Pharmaceuticals receives A$801,604 in R&D rebate advance

Recce Pharmaceuticals — Gearing up for more R327 studies

Recce Pharmaceuticals — Gearing up for more R327 studies

Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial

Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial

Recce Pharmaceuticals lands ethics approval for expanded UTI studies

Recce Pharmaceuticals lands ethics approval for expanded UTI studies

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott

Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott

Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023

Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023